The CARS1 UNE-C1 domain shows a synergistic effect with cancer antigens and several immune checkpoint inhibitors in in vivo cancer models, suggesting further potential for the domain to be developed as an immunoadjuvant to activate antitumor immunity. The gene discussed is CARS1; the disease is cancer.